Summary

DelveInsight’s, LAG-3 Antagonists, TIM-3 Antagonists & OX40 AgonistsPipeline Insights, 2015, provides the in-depth analysis of the pipeline assets across the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists. The main objective of this report to track competitor pipeline molecules, related research activities, technology, collaborations, in-licensing and out-licensing deals. The LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Report helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight’s, LAG-3 Antagonists, TIM-3 Antagonists & OX40 AgonistsPipeline Insights, 2015 Report covers the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline molecules at various stages of development like Pre-registration phase, clinical phases (Phase III, Phase II & Phase I), pre-clinical and discovery phases. The Report also provides LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists related therapeutic assessments by molecule type, route of administration, monotherapy and combination products. The Report also highlights the discontinued and inactive projects in pipeline for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• DelveInsight’s report provides a LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Landscape across the globe
• The report provides drug profiles which includes product description, MOA, licensors & collaborators,  technology, development partner and chemical information
• Coverage of the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists and also provide company profiling
• Pipeline products coverage based on various stages of development from NDA filings to discovery.
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Reasons to buy

• Complete Pipeline intelligence and complete understanding over therapeutics development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
• Track your competitors and develop strategic initiatives to support your drug development activities.
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
• Understand the market and choose right partners for in-licensing and out licensing for your valuable assets
• Understand the factors behind failed/discontinued projects and move ahead without leaving any stone unturned

Table of contents

• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Overview
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Disease Associated
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Pipeline Therapeutics
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Therapeutics under Development by Companies
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Late Stage Products (Filed and Phase III)
• Comparative Analysis
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Mid Clinical Stage Products (Phase II)
• Comparative Analysis
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Early Clinical Stage Products (Phase I and IND Filed)
• Comparative Analysis
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists – Discontinued Products
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists – Dormant Products
• Companies Involved in Therapeutics Development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables

• Number of Products under Development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists by Therapy Area, 2015
• Number of Products under Development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists, 2015
• Number of Products under Development by Companies
• Comparative Analysis by Late Clinical Stage Products (Filed and Phase III), 2015
• Comparative Analysis Mid Clinical Stage Products (Phase II), 2015
• Comparative Analysis Early Clinical Stage Products (Phase I and IND Filed), 2015
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2015
• Drug Candidates Profiles
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Assessment by Monotherapy Products
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Assessment by Combination Products
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Assessment by Route of Administration
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Assessment by Stage and Route of Administration
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Assessment by Molecule Type
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Assessment by Stage and Molecule Type
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Therapeutics – Discontinued Products
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Therapeutics – Dormant Products
• Products under Development by Companies, 2015

List of Figures

• Number of Products under Development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists by Therapy Area, 2015
• Number of Products under Development for LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists, 2015
• Late Clinical Stage Products (Filed and Phase III), 2015
• Mid Clinical Stage Products (Phase II), 2015
• Early Clinical Stage Products (Phase I and IND Filed), 2015
• Discovery and Pre-Clinical Stage Products, 2015
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Assessment by Monotherapy Products
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Assessment by Combination Products
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Assessment by Route of Administration
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Assessment by Stage and Route of Administration
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Assessment by Molecule Type
• LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Assessment by Stage and Molecule Type